Peritoneoscopy: A Valuable Staging Tool in Ovarian Carcinoma

  1. STEPHEN H. ROSENOFF, M.D.;
  2. ROBERT C. YOUNG, M.D., F.A.C.P.;
  3. TOM ANDERSON, M.D.;
  4. CHARLES BAGLEY, M.D.;
  5. BRUCE CHABNER, M.D., F.A.C.P.;
  6. PHILIP S. SCHEIN, M.D., F.A.C.P.;
  7. SUSAN HUBBARD, R.N.; and
  8. VINCENT T. DeVITA, M.D., F.A.C.P.
  1. Charlottesville, Virginia, Washington, D.C., and Bethesda, Maryland

    Abstract

    Peritoneoscopy was done within 1 month of exploratory laparotomy in 30 consecutive patients, with ovarian carcinoma as part of their pretreatment evaluation. Six of the 7 patients who were thought to have ovarian carcinoma localized to the pelvis (stages I and II) were found to have advanced disease (stage III) at peritoneoscopy and thus required a change in therapy. Metastatic diaphragmatic involvement in ovarian carcinoma is common and was found in 77% of all patients studied. The routine shielding of the liver area ordinarily used with total abdominal radiotherapy would select these patients for therapeutic failure. Peritoneoscopy supplied reevaluate findings in 2 of the 7 patients having normal physical, roentgenologic, and laboratory examinations, as well as in 93% of all patients studied. "Second look" peritoneoscopy precluded the need for laparotomy in 5 of 13 patients achieving an apparent clinical remission.

    Article and Author Information

    • ▸From the Medicine Branch, National Cancer Institute, Bethesda, Maryland.

    • ▸Requests for reprints should be addressed to Robert C. Young, M.D., Bldg. 10 12N-226, National Institutes of Health, Bethesda, MD 20014.

    « Previous | Next Article »Table of Contents